Thursday, July 23, 2026

Chemical, PFAS and Platform Dockets Drive Concentrated Intake

Chemical-exposure claims again set the filing pace as Hair Relaxer Marketing, Sales Practices, and Products Liability (3060) drew 16 complaints, with Ashcraft Gerel LLP and Singleton Schreiber LLP supplying four each and underscoring the docket’s concentrated repeat intake. Aqueous Film-Forming Foams Products Liability (2873) followed with 14 filings led by Napoli Shkolnik’s five, while Culpepper & Associates and P.o Box 55811 added to the environmental docket’s broader claimant mix. Platform and passenger-assault matters each added nine: Weitz & Luxenberg PC and Frantz Law Group APLC led Social Media Adolescent Addiction Personal Injury Products Liability (3047), while Cutter Law PC and Wagstaff Law Firm each filed four in Uber Passenger Sexual Assault (3084). Pharmaceutical intake remained equally active in Depo-Provera (3140), where Murphy Law Firm filed four of nine complaints and Bryant Law Center PSC added one, keeping the day’s top tier diversified across established dockets. See the full filing feed and firm-level breakdowns here.

Keytruda Research Adds Cardiovascular-Risk Context

On July 22, 2026, Keytruda Organ Failure gained a current research marker when PubMed published Comparative Risk of Cardiovascular Hospitalization With Immune Checkpoint Inhibitors Versus Chemotherapy. The study’s comparative frame addresses cardiovascular hospitalization among immune checkpoint inhibitor treatment and chemotherapy, placing treatment-related cardiovascular risk in a current clinical-evidence context. It does not attribute any particular hospitalization or organ injury to Keytruda, establish product defect or causation, or resolve an individual claim. For counsel, the publication supplies a fresh reference point for testing the fit between class-level cardiovascular outcomes and product-specific expert causation opinions.

Sublingual-Delivery Review Adds Suboxone Context

On July 21, 2026, Suboxone Teeth received a related clinical research update through Sublingual Administration for Pain Control: Pharmacology, Clinical Applications and Future Directions. The publication examines sublingual drug delivery in pain care, with pharmacology, clinical applications, and future directions as its stated focus. It does not decide whether a Suboxone formulation caused dental injury, establish a mechanism in any individual action, or resolve litigation merits. Its immediate significance is as current context for evaluating how experts distinguish delivery-route evidence from product-specific causation proof.